Status:

COMPLETED

Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis

Lead Sponsor:

Swedish Orphan Biovitrum

Conditions:

Primary Hemophagocytic Lymphohistiocytosis

Eligibility:

All Genders

Up to 18 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to expand the knowledge on the efficacy and safety of emapalumab (previously known as NI-0501) as a treatment for primary haemophagocytic lymphohistiocytosis (HLH) patient...

Eligibility Criteria

Inclusion

  • Main
  • Primary HLH patients with active disease.
  • Treatment naïve patients or patients having already received HLH conventional therapy, but having not responded, not achieved a satisfactory response or worsened, or reactivated, or are unable to tolerate current standard of care.
  • Informed consent signed by the patient or by the patient's legally authorized representative.
  • Received guidance on contraception.
  • Main

Exclusion

  • Diagnosis of secondary HLH consequent to a proven rheumatic, metabolic or neoplastic disease.
  • Active mycobacteria, Histoplasma capsulatum, Shigella, Salmonella, Campylobacter or Leishmania infections.
  • Evidence of latent tuberculosis.
  • Presence of malignancy.
  • Concomitant disease or malformation severely affecting cardiovascular, pulmonary, central nervous system (CNS), liver, or renal function, that in the opinion of the Investigator may significantly affect the likelihood to respond to treatment and/or the assessment of emapalumab safety and/or efficacy.
  • History of hypersensitivity or allergy to any component of the study regimen.
  • Receipt of a BCG vaccine within 12 weeks prior to Screening.
  • Receipt of a live or attenuated-live (other than BCG) vaccine within 6 weeks prior to Screening.
  • Pregnant or lactating female patients.

Key Trial Info

Start Date :

February 6 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 14 2022

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT03312751

Start Date

February 6 2019

End Date

September 14 2022

Last Update

March 12 2024

Active Locations (27)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (27 locations)

1

Phoenix Children Hospital

Phoenix, Arizona, United States, 85016

2

Children's Hospital Los Angeles

Los Angeles, California, United States, 90027

3

Children's Hospital Colorado

Aurora, Colorado, United States, 80045-7106

4

Alfred I. duPont Hospital for Children - Nemours Center for Cancer and Blood Disorders - Division of Pediatric Hematology Oncology

Wilmington, Delaware, United States, 19803